Literature DB >> 27926717

Alnylam terminates revusiran program, stock plunges.

Ken Garber.   

Abstract

Year:  2016        PMID： 27926717     DOI： 10.1038/nbt1216-1213

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Expression profiling reveals off-target gene regulation by RNAi.

Authors:  Aimee L Jackson; Steven R Bartz; Janell Schelter; Sumire V Kobayashi; Julja Burchard; Mao Mao; Bin Li; Guy Cavet; Peter S Linsley
Journal:  Nat Biotechnol       Date:  2003-05-18       Impact factor: 54.908

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  Alnylam's RNAi therapy targets amyloid disease.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908
  3 in total
  17 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

2.  Alnylam launches era of RNAi drugs.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2018-09-06       Impact factor: 54.908

Review 3.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

4.  With Alnylam's amyloidosis success, RNAi approval hopes soar.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

5.  Public biotech in 2016-the numbers.

Authors:  Chris Morrison; Riku Lähteenmäki
Journal:  Nat Biotechnol       Date:  2017-07-12       Impact factor: 54.908

Review 6.  Evaluation and control of miRNA-like off-target repression for RNA interference.

Authors:  Heeyoung Seok; Haejeong Lee; Eun-Sook Jang; Sung Wook Chi
Journal:  Cell Mol Life Sci       Date:  2017-09-13       Impact factor: 9.261

7.  Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone.

Authors:  Ryan Reshke; James A Taylor; Alexandre Savard; Huishan Guo; Luke H Rhym; Piotr S Kowalski; My Tran Trung; Charles Campbell; Wheaton Little; Daniel G Anderson; Derrick Gibbings
Journal:  Nat Biomed Eng       Date:  2020-01-14       Impact factor: 25.671

Review 8.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

9.  5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.

Authors:  Reka A Haraszti; Loic Roux; Andrew H Coles; Anton A Turanov; Julia F Alterman; Dimas Echeverria; Bruno M D C Godinho; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

10.  Exosome-mediated delivery of RNA and DNA for gene therapy.

Authors:  Radha Munagala; Farrukh Aqil; Jeyaprakash Jeyabalan; Raghuram Kandimalla; Margaret Wallen; Neha Tyagi; Sarah Wilcher; Jun Yan; David J Schultz; Wendy Spencer; Ramesh C Gupta
Journal:  Cancer Lett       Date:  2021-02-18       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.